AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17405770 — intervention group
Group type: COMPARATOR
Intervention: Myocardial Infarction (MI)
Number of subjects: 8309
Study 16291100 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital lumbar stenosis group (20 patients)
Number of subjects: 40
Study 11571096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg oral methyltestosterone (meT) in combination with 0.625 mg oral esterified estrogen (E)
Number of subjects: 35
Study 11571096 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg oral esterified estrogen (E) alone
Number of subjects: 35
Study 9262254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Number of subjects: 65
Study 9262254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 65
Study 9262254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 324 mg
Number of subjects: 65
Study 9262254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 40.5 mg
Number of subjects: 65
Study 9262254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 7898011 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual approach to immune correction
Number of subjects: 57
Study 7898011 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐ and B‐lymphocyte systems
Number of subjects: 57
Study 3311133 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal position
Number of subjects: 58
Study 3311133 — intervention group
Group type: COMPARATOR
Intervention: 15 degrees lateral tilt position
Number of subjects: 58
Study 30557879 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term steroid regimen (prednisolone 0.8-1.0 mg/kg/day for 4-6 weeks, then 0.5-0.6 mg/kg/alternate day for 4 weeks)
Number of subjects: 35
Study 30557879 — intervention group
Group type: COMPARATOR
Intervention: Conventional steroid administration (control group, n = 140)
Number of subjects: 35
Study 28746934 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvianolate
Number of subjects: 484
Study 22821285 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium intake (μg/day/1,000 kcal)
Number of subjects: 39
Study 22821285 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake (mg/day/1,000 kcal)
Number of subjects: 39
Study 22821285 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of total energy from dairy products
Number of subjects: 39
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step screening for gestational diabetes
Number of subjects: 152
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step screening for gestational diabetes
Number of subjects: 152
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal testing initiation for medication-treated gestational diabetes
Number of subjects: 152
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal testing initiation for diet-treated gestational diabetes
Number of subjects: 152
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort in treating non-pregnant women with Type 2 diabetes
Number of subjects: 152
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for Type 2 diabetes post-delivery
Number of subjects: 152
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of glibenclamide (glyburide)
Number of subjects: 152
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section based on fetal weight
Number of subjects: 152
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating exercise post-delivery
Number of subjects: 152
Study 21535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Checking 2-h postprandial glucose levels
Number of subjects: 152
Study 18692175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg, titratable to 30 or 60 mg) once daily for 30 days
Number of subjects: 19
Study 18692175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16442328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and stable fibrillatory frequency
Number of subjects: 50
Study 16442328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low exponential decay
Number of subjects: 50
Study 16442328 — intervention group
Group type: COMPARATOR
Intervention: Fibrillation amplitude
Number of subjects: 50
Study 16442328 — intervention group
Group type: COMPARATOR
Intervention: Complexity measures
Number of subjects: 50
Study 12185505 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy with CEOP-Bleo (cyclophosphamide 750 mg/m(2), vincristine 1.4 mg/m(2), prednisone 40 mg/m(2), epirubicin 70 mg/m(2), and bleomycin 10 mg/m(2)) every 21 days for six cycles followed by radiotherapy (35-45 Gy, mean 38 Gy)
Number of subjects: 68
Study 12185505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy with mega CEOP-Bleo (cyclophosphamide 1000 mg/m(2), epirubicin 120 mg/m(2), vincristine, prednisone, and bleomycin at the same doses) every 21 days for six cycles followed by radiotherapy (35-45 Gy, mean 38 Gy)
Number of subjects: 68
Study 10418699 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (2500 lux)
Number of subjects: 38
Study 10418699 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared light (0.18 lux)
Number of subjects: 38
Study 10418699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no light treatment)
Number of subjects: 38
Study 8618810 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis with cuprophan dialyser used first time
Number of subjects: 42
Study 8618810 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis with cuprophan dialyser used more than three times
Number of subjects: 42
Study 1675518 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PUVA
Number of subjects: 15
Study 1675518 — intervention group
Group type: COMPARATOR
Intervention: UVA
Number of subjects: 15
Study 6947693 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological testing for motivation
Number of subjects: 70
Study 6947693 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Orthodontics Construct of Cooperation (SOCC)
Number of subjects: 70
Study 6947693 — intervention group
Group type: EXPERIMENTAL
Intervention: Perio-Orthodontic Construct of Cooperation (POCC)
Number of subjects: 70
Study 28749158 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy treatment (TF-CBT-anger)
Number of subjects: 78
Study 28749158 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 78
Study 27376410 — intervention group
Group type: EXPERIMENTAL
Intervention: MammoMARK™
Number of subjects: 80
Study 27376410 — intervention group
Group type: EXPERIMENTAL
Intervention: HydroMARK(®)
Number of subjects: 80
Study 27376410 — intervention group
Group type: EXPERIMENTAL
Intervention: SecurMark(®)
Number of subjects: 80
Study 27376410 — intervention group
Group type: EXPERIMENTAL
Intervention: MammoStar™
Number of subjects: 80
Study 27376410 — intervention group
Group type: EXPERIMENTAL
Intervention: All markers
Number of subjects: 80
Study 24755139 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g RBEP (rice bran exo‐biopolymer)
Number of subjects: 80
Study 24755139 — intervention group
Group type: COMPARATOR
Intervention: 3 g placebo
Number of subjects: 80
Study 22922813 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary ultrafiltration (sUF)
Number of subjects: 26
Study 22922813 — intervention group
Group type: COMPARATOR
Intervention: Regular hemodialysis (rHD)
Number of subjects: 26
Study 20384669 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 105
Study 20384669 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solution
Number of subjects: 105
Study 20384669 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 19227650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with natural rubber latex (NRL) for 3 years
Number of subjects: 12
Study 15948087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer adherence group (n = 20)
Number of subjects: 38
Study 15948087 — intervention group
Group type: COMPARATOR
Intervention: Non-adherence group (n = 18)
Number of subjects: 38
Study 12559481 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (N=12)
Number of subjects: 21
Study 12559481 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (N=9)
Number of subjects: 21
Study 10075387 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks in Birmingham with lower education level
Number of subjects: 435
Study 10075387 — intervention group
Group type: EXPERIMENTAL
Intervention: Whites in Birmingham with lower education level
Number of subjects: 435
Study 10075387 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks with lower education level in both cities
Number of subjects: 435
Study 10075387 — intervention group
Group type: COMPARATOR
Intervention: Whites
Number of subjects: 435
Study 7677473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed with fibrin glue
Number of subjects: 36
Study 7677473 — intervention group
Group type: COMPARATOR
Intervention: Reinforced with pledgets
Number of subjects: 36
Study 2167800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral frusemide
Number of subjects: 14
Study 2167800 — intervention group
Group type: EXPERIMENTAL
Intervention: Desamino‐D‐arginine‐vasopressin
Number of subjects: 14
Study 2167800 — intervention group
Group type: EXPERIMENTAL
Intervention: Water loading
Number of subjects: 14
Study 7324942 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day treatment with sulfafurazole
Number of subjects: 235
Study 7324942 — intervention group
Group type: EXPERIMENTAL
Intervention: 42-day treatment
Number of subjects: 235
Study 7324942 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day treatment
Number of subjects: 235
Study 30679107 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of S-1 (80 mg/day per m2 for 4 weeks followed by 2 weeks rest)
Number of subjects: 590
Study 30679107 — intervention group
Group type: COMPARATOR
Intervention: Eight courses of S-1 (80 mg/day per m2 for 4 weeks followed by 2 weeks rest)
Number of subjects: 590
Study 30679107 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of S-1
Number of subjects: 590
Study 30679107 — intervention group
Group type: COMPARATOR
Intervention: Eight courses of S-1
Number of subjects: 590
Study 28093609 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal femoral locking plate alone (group I)
Number of subjects: 21
Study 28093609 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal femoral locking plate with cerclage cable (group II)
Number of subjects: 21
Study 26858958 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (additional to DMP), running over 24 months, including peer supporter recruitment, training, weekly physical exercise meetings, and monthly discussions on diabetes-related topics.
Number of subjects: 337
Study 26858958 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 337
Study 24507553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Online e-learning modules
Number of subjects: 154
Study 24507553 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 154
Study 22723469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal swab tested by rRT‐PCR
Number of subjects: 240
Study 22723469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab tested by rRT‐PCR
Number of subjects: 240
Study 20873252 — intervention group
Group type: EXPERIMENTAL
Intervention: panto‐magnesium pearl baths
Number of subjects: 49
Study 20873252 — intervention group
Group type: COMPARATOR
Intervention: magnetotherapy, manual massage and exercise therapy
Number of subjects: 49
Study 17407654 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder calls
Number of subjects: 504
Study 17407654 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 504
Study 17407654 — intervention group
Group type: EXPERIMENTAL
Intervention: Not contactable group
Number of subjects: 504
Study 15910951 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation by nurses in addition to standard treatment
Number of subjects: 163
Study 15910951 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 163
Study 11876704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based triple regimens (treatment group)
Number of subjects: 27
Study 11876704 — intervention group
Group type: COMPARATOR
Intervention: No treatment (no treatment group)
Number of subjects: 27
Study 10606847 — intervention group
Group type: EXPERIMENTAL
Intervention: Locobase(R) fatty cream containing a mixture of 5% lactic acid and 20% propylene glycol (LPL)
Number of subjects: 20
Study 10606847 — intervention group
Group type: EXPERIMENTAL
Intervention: Essex(R) (Diprobase(R)) cream (LPE)
Number of subjects: 20
Study 10606847 — intervention group
Group type: COMPARATOR
Intervention: Locobase(R) fatty cream containing 5% urea
Number of subjects: 20
Study 10606847 — intervention group
Group type: COMPARATOR
Intervention: Locobase(R) fatty cream containing 20% propylene glycol
Number of subjects: 20
Study 1289508 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 42
Study 1289508 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 42
Study 6085375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (2 X 10 to 2 X 20 mg/day)
Number of subjects: 25
Study 6085375 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (2 X 80 to 2 X 160 mg/day)
Number of subjects: 25
Study 6085375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 25
Study 6085375 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 25
Study 30473390 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed school start time to 10:00am
Number of subjects: 100
Study 30473390 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based sleep education programme
Number of subjects: 100
Study 30473390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of delayed start time and sleep education programme
Number of subjects: 100
Study 30473390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 30309835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, therapist-guided internet-based cognitive behavioral therapy (ICBT)
Number of subjects: 1000
Study 30309835 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 1000
Study 26201436 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping cards (n = 32)
Number of subjects: 64
Study 26201436 — intervention group
Group type: COMPARATOR
Intervention: Case management only (n = 32)
Number of subjects: 64
Study 25620449 — intervention group
Group type: EXPERIMENTAL
Intervention: SB building-level intervention
Number of subjects: 117
Study 23582138 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl plus open-label boluses of fentanyl
Number of subjects: 131
Study 23582138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (continuous infusion of placebo plus open-label boluses of fentanyl)
Number of subjects: 131
Study 20872323 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding
Number of subjects: 52
Study 20872323 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral feeding
Number of subjects: 52
Study 18394499 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release massage
Number of subjects: 62
Study 18394499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham treatment with disconnected ultrasound and magnetotherapy equipment)
Number of subjects: 62
Study 16451396 — intervention group
Group type: EXPERIMENTAL
Intervention: ProME(Epidoxorubicin)CE-CytaBOM (PE-C)
Number of subjects: 356
Study 16451396 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMI(Idarubicin)CE-CytaBOM (PI-C)
Number of subjects: 356
Study 16451396 — intervention group
Group type: COMPARATOR
Intervention: ProME(Epidoxorubicin)CE-CytaBOM (PE-C) and ProMI(Idarubicin)CE-CytaBOM (PI-C)
Number of subjects: 356
Study 16451396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible treatment schedule
Number of subjects: 356
Study 16451396 — intervention group
Group type: COMPARATOR
Intervention: Fixed treatment schedule
Number of subjects: 356
Study 16451396 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IPI 3-5
Number of subjects: 356
Study 12920631 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6
Study 12920631 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 6
Study 10805697 — intervention group
Group type: COMPARATOR
Intervention: Shoulder free condition
Number of subjects: 0
Study 10805697 — intervention group
Group type: COMPARATOR
Intervention: Shoulder fixed condition
Number of subjects: 0
Study 9224834 — intervention group
Group type: EXPERIMENTAL
Intervention: First-order motion stimuli
Number of subjects: 0
Study 9224834 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-order motion stimuli
Number of subjects: 0
Study 9224834 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow second-order stimuli
Number of subjects: 0
Study 8015881 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (iv 100 mg/kg/d, then oral 50 mg/kg/d after 48 hours afebrile)
Number of subjects: 64
Study 8015881 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin (100,000 IU/kg/d) + netilmicin (5 mg/kg/d) + metronidazole (30 mg/kg/d) (iv, then oral metronidazole 30 mg/kg/d)
Number of subjects: 64
Study 3323609 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion with somatostatin and hormone replacement (insulin/glucagon/growth hormone)
Number of subjects: 0
Study 3323609 — intervention group
Group type: COMPARATOR
Intervention: Amino acid infusion alone
Number of subjects: 0
Study 31530424 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ (SC)
Number of subjects: 61
Study 31530424 — intervention group
Group type: COMPARATOR
Intervention: Active-control (AC)
Number of subjects: 61
Study 29761861 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD plus medical therapy
Number of subjects: 3359
Study 29761861 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 3359
Study 27149561 — intervention group
Group type: EXPERIMENTAL
Intervention: Size modulation standard automated perimetry (SM‐SAP)
Number of subjects: 88
Study 27149561 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard automated perimetry (C‐SAP)
Number of subjects: 88
Study 25178073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of nebivolol and amlodipine (n=62)
Number of subjects: 124
Study 25178073 — intervention group
Group type: COMPARATOR
Intervention: Free combination of nebivolol and amlodipine (n=62)
Number of subjects: 124
Study 22863282 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 59
Study 22863282 — intervention group
Group type: COMPARATOR
Intervention: Scheduled intravenous analgesia (nurse-administered hydromorphone)
Number of subjects: 59
Study 22863282 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 59
Study 20194309 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile compression device
Number of subjects: 410
Study 20194309 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 410
Study 18206525 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehome monitoring (video conferencing and phone line transmission of weight, blood pressure, and electrocardiograms)
Number of subjects: 0
Study 18206525 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehome monitoring
Number of subjects: 0
Study 15764242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme
Number of subjects: 197
Study 15764242 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 197
Study 15764242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme (non-smokers subgroup)
Number of subjects: 197
Study 15764242 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-smokers subgroup)
Number of subjects: 197
Study 14532151 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 chimeric monoclonal antibody)
Number of subjects: 0
Study 10561229 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB (cisplatin, dacarbazine, carmustine)
Number of subjects: 184
Study 10561229 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB + TAM (cisplatin, dacarbazine, carmustine + tamoxifen)
Number of subjects: 184
Study 8673528 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 500 mg/d
Number of subjects: 400
Study 8673528 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 200 mg/d
Number of subjects: 400
Study 8673528 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine 600 mg/d
Number of subjects: 400
Study 1499856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous portal insulin infusion (IPII) via the umbilical vein for 4 months
Number of subjects: 12
Study 1499856 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII) for 4 months
Number of subjects: 12
Study 1499856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 6540532 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose prednisolone (60 mg/m2/day p.o. for 21 days)
Number of subjects: 73
Study 30688865 — intervention group
Group type: EXPERIMENTAL
Intervention: Interset Stretching (ISS)
Number of subjects: 29
Study 30688865 — intervention group
Group type: COMPARATOR
Intervention: Traditional Strength Training (TST)
Number of subjects: 29
Study 29904126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (n=49)
Number of subjects: 100
Study 29904126 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (n=51)
Number of subjects: 100
Study 27227691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramicronized palmitoylethanolamide (PEA-um)
Number of subjects: 68
Study 27227691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 24606997 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 16
Study 24606997 — intervention group
Group type: COMPARATOR
Intervention: Sham whole-body vibration (SWBV)
Number of subjects: 16